331 related articles for article (PubMed ID: 28906010)
1. Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b.
Ogasawara N; Kobayashi M; Akuta N; Kominami Y; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Suzuki F; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kobayashi M; Kumada H
J Med Virol; 2018 Feb; 90(2):313-319. PubMed ID: 28906010
[TBL] [Abstract][Full Text] [Related]
2. Improvement of liver stiffness in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response.
Tada T; Kumada T; Toyoda H; Mizuno K; Sone Y; Kataoka S; Hashinokuchi S
J Gastroenterol Hepatol; 2017 Dec; 32(12):1982-1988. PubMed ID: 28299813
[TBL] [Abstract][Full Text] [Related]
3. Favorable efficacy of daclatasvir plus asunaprevir in treatment of elderly Japanese patients infected with HCV genotype 1b aged 70 and older.
Akuta N; Sezaki H; Suzuki F; Kawamura Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
J Med Virol; 2017 Jan; 89(1):91-98. PubMed ID: 27256744
[TBL] [Abstract][Full Text] [Related]
4. Changes in liver stiffness and steatosis among patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response.
Kobayashi N; Iijima H; Tada T; Kumada T; Yoshida M; Aoki T; Nishimura T; Nakano C; Takata R; Yoh K; Ishii A; Takashima T; Sakai Y; Aizawa N; Nishikawa H; Ikeda N; Iwata Y; Enomoto H; Hirota S; Fujimoto J; Nishiguchi S
Eur J Gastroenterol Hepatol; 2018 May; 30(5):546-551. PubMed ID: 29494353
[TBL] [Abstract][Full Text] [Related]
5. Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection.
Akuta N; Toyota J; Karino Y; Ikeda F; Ido A; Tanaka K; Takaguchi K; Naganuma A; Tomita E; Chayama K; Fujiyama S; Inada Y; Yoshiji H; Watanabe H; Ishikawa H; McPhee F; Noviello S; Kumada H
J Gastroenterol; 2018 Sep; 53(9):1089-1097. PubMed ID: 29500489
[TBL] [Abstract][Full Text] [Related]
6. Durability of Sustained Virologic Response and Improvement of Fibrosis Markers after Daclatasvir and Asunaprevir Treatment in Genotype 1b Hepatitis C Virus-Infected Patients: a Real Life and Multicenter Study.
Shin SK; Lee JW; Ra H; Kwon OS; Shin JB; Jin YJ; Lee S; Han KJ; Kim YN; Kim TH; Kim YS; Kim JH
J Korean Med Sci; 2019 Oct; 34(41):e264. PubMed ID: 31650719
[TBL] [Abstract][Full Text] [Related]
7. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.
Manns M; Pol S; Jacobson IM; Marcellin P; Gordon SC; Peng CY; Chang TT; Everson GT; Heo J; Gerken G; Yoffe B; Towner WJ; Bourliere M; Metivier S; Chu CJ; Sievert W; Bronowicki JP; Thabut D; Lee YJ; Kao JH; McPhee F; Kopit J; Mendez P; Linaberry M; Hughes E; Noviello S;
Lancet; 2014 Nov; 384(9954):1597-605. PubMed ID: 25078304
[TBL] [Abstract][Full Text] [Related]
8. Outcomes for Cirrhotic Patients with Hepatitis C Virus 1b Treated with Asunaprevir and Daclatasvir Combination.
Tamori A; Hai H; Uchida-Kobayashi S; Enomoto M; Kozuka R; Motoyama H; Kawamura E; Hagihara A; Teranishi Y; Yoshida K; Morikawa H; Murakami Y; Kawada N
Ann Hepatol; 2017; 16(5):734-741. PubMed ID: 28809743
[TBL] [Abstract][Full Text] [Related]
9. Serum asunaprevir concentrations showing correlation with the extent of liver fibrosis as a factor inducing liver injuries in patients with genotype-1b hepatitis C virus receiving daclatasvir plus asunaprevir therapy.
Uchida Y; Naiki K; Kouyama JI; Sugawara K; Nakao M; Motoya D; Inao M; Nakayama N; Imai Y; Tomiya T; Mochida S
PLoS One; 2018; 13(10):e0205600. PubMed ID: 30308053
[TBL] [Abstract][Full Text] [Related]
10. Dynamics of liver stiffness values by means of transient elastography in patients with HCV liver cirrhosis undergoing interferon free treatment.
Sporea I; Lupușoru R; Mare R; Popescu A; Gheorghe L; Iacob S; Șirli R
J Gastrointestin Liver Dis; 2017 Jun; 26(2):145-150. PubMed ID: 28617884
[TBL] [Abstract][Full Text] [Related]
11. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience.
Dolmazashvili E; Abutidze A; Chkhartishvili N; Karchava M; Sharvadze L; Tsertsvadze T
Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1223-1230. PubMed ID: 28857900
[TBL] [Abstract][Full Text] [Related]
12. The change in liver stiffness, controlled attenuation parameter and fibrosis-4 index for chronic hepatitis C patients with direct-acting antivirals.
Lee YC; Hu TH; Hung CH; Lu SN; Chen CH; Wang JH
PLoS One; 2019; 14(4):e0214323. PubMed ID: 30939158
[TBL] [Abstract][Full Text] [Related]
13. Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection.
Wei L; Wang FS; Zhang MX; Jia JD; Yakovlev AA; Xie W; Burnevich E; Niu JQ; Jung YJ; Jiang XJ; Xu M; Chen XY; Xie Q; Li J; Hou JL; Tang H; Dou XG; Gandhi Y; Hu WH; McPhee F; Noviello S; Treitel M; Mo L; Deng J
World J Gastroenterol; 2018 Mar; 24(12):1361-1372. PubMed ID: 29599611
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
Everson GT; Sims KD; Rodriguez-Torres M; Hézode C; Lawitz E; Bourlière M; Loustaud-Ratti V; Rustgi V; Schwartz H; Tatum H; Marcellin P; Pol S; Thuluvath PJ; Eley T; Wang X; Huang SP; McPhee F; Wind-Rotolo M; Chung E; Pasquinelli C; Grasela DM; Gardiner DF
Gastroenterology; 2014 Feb; 146(2):420-9. PubMed ID: 24184132
[TBL] [Abstract][Full Text] [Related]
15. Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals.
Noureddin M; Wong MM; Todo T; Lu SC; Sanyal AJ; Mena EA
World J Gastroenterol; 2018 Mar; 24(11):1269-1277. PubMed ID: 29568207
[TBL] [Abstract][Full Text] [Related]
16. Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir + Asunaprevir therapy in Korean patients with genotype 1b hepatitis C.
Yu JH; Lee JI; Lee KS; Kim JK
Virol J; 2017 Aug; 14(1):164. PubMed ID: 28836992
[TBL] [Abstract][Full Text] [Related]
17. Late relapse of hepatitis C virus in patients with sustained virological response after daclatasvir and asunaprevir therapy.
Hayashi K; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Hirooka Y; Toyoda H; Kumada T; Hattori M; Katano Y; Goto H
J Viral Hepat; 2018 Dec; 25(12):1446-1451. PubMed ID: 29993164
[TBL] [Abstract][Full Text] [Related]
18. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders.
Lok AS; Gardiner DF; Hézode C; Lawitz EJ; Bourlière M; Everson GT; Marcellin P; Rodriguez-Torres M; Pol S; Serfaty L; Eley T; Huang SP; Li J; Wind-Rotolo M; Yu F; McPhee F; Grasela DM; Pasquinelli C
J Hepatol; 2014 Mar; 60(3):490-9. PubMed ID: 24444658
[TBL] [Abstract][Full Text] [Related]
19. Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals.
Ravaioli F; Conti F; Brillanti S; Andreone P; Mazzella G; Buonfiglioli F; Serio I; Verrucchi G; Bacchi Reggiani ML; Colli A; Marasco G; Colecchia A; Festi D
Dig Liver Dis; 2018 Jun; 50(6):573-579. PubMed ID: 29567413
[TBL] [Abstract][Full Text] [Related]
20. Viral eradication reduces both liver stiffness and steatosis in patients with chronic hepatitis C virus infection who received direct-acting anti-viral therapy.
Tada T; Kumada T; Toyoda H; Sone Y; Takeshima K; Ogawa S; Goto T; Wakahata A; Nakashima M; Nakamuta M; Tanaka J
Aliment Pharmacol Ther; 2018 Apr; 47(7):1012-1022. PubMed ID: 29424449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
